Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis-Reference-Cited by-同舟云学术

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis

Published:2018-08 Issue:31 Volume:97 Page:e11518
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Golabi Pegah,Bush Haley,Stepanova Maria,Locklear Cameron T.,Jacobson Ira M.,Mishra Alita,Trimble Gregory,Erario Madeline,Venkatesan Chapy,Younossi Issah,Goodman Zachary,Younossi Zobair M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference36 articles.

1. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008;Younossi;Clin Gastroenterol Hepatol,2011

2. The global NAFLD epidemic;Loomba;Nat Rev Gastroenterol Hepatol,2013

3. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994;Lazo;Am J Epidemiol,2013

4. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey;Ford;JAMA,2002

5. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States;Wong;Gastroenterology,2015

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of county-level food access on the mortality and post-transplant survival among patients with steatotic liver disease;Surgery;2024-07

2. Epidemiology of NAFLD – Focus on diabetes;Diabetes Research and Clinical Practice;2024-04

3. Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease;Alimentary Pharmacology & Therapeutics;2024-01-21

4. Liver transplantation: the recipient;Living Donor Organ Transplantation;2024

5. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction–associated steatotic liver disease and alcohol-associated liver disease;Hepatology Communications;2023-12-22